MedPath

PFIZER INC.

PFIZER INC. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Other: Placebo
First Posted Date
2009-04-20
Last Posted Date
2022-10-21
Lead Sponsor
Pfizer
Target Recruit Count
195
Registration Number
NCT00883896
Locations
πŸ‡ΊπŸ‡Έ

Arizona Arthritis & Rheumatology Research, PLLC, Glendale, Arizona, United States

πŸ‡ΊπŸ‡Έ

Desert Medical Advances, Palm Desert, California, United States

πŸ‡ΊπŸ‡Έ

Arthritis Center, Palm Harbor, Florida, United States

and more 49 locations

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

Phase 4
Terminated
Conditions
Hemophilia A
Interventions
Drug: moroctocog alfa (AF-CC) (ReFacto AF)
Procedure: Laboratory tests
First Posted Date
2009-04-20
Last Posted Date
2014-09-01
Lead Sponsor
Pfizer
Target Recruit Count
208
Registration Number
NCT00884390
Locations
πŸ‡¬πŸ‡§

Pfizer Investigational Site, Manchester, United Kingdom

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
First Posted Date
2009-04-13
Last Posted Date
2021-09-27
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT00880009
Locations
πŸ‡ΊπŸ‡Έ

American Institute of Research, Whittier, California, United States

πŸ‡ΊπŸ‡Έ

Joliet Oncology Hematology Associates, Joliet, Illinois, United States

πŸ‡ΊπŸ‡Έ

Oncology Specialists SC, Niles, Illinois, United States

and more 8 locations

An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2009-04-13
Last Posted Date
2010-06-14
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT00879983
Locations
πŸ‡¨πŸ‡³

Pfizer Investigational Site, Shanghai, China

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Phase 1
Completed
Conditions
Meningitis, Meningococcal
Interventions
Biological: rLP2086 vaccine or control
First Posted Date
2009-04-13
Last Posted Date
2015-08-06
Lead Sponsor
Pfizer
Target Recruit Count
48
Registration Number
NCT00879814
Locations
πŸ‡ΊπŸ‡Έ

Miami Research Associates, Inc., South Miami, Florida, United States

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Malignancy
Neoplasms
Advanced Solid Tumors
Carcinoma
Cancer
Interventions
Biological: CVX-060
First Posted Date
2009-04-10
Last Posted Date
2015-01-26
Lead Sponsor
Pfizer
Target Recruit Count
34
Registration Number
NCT00879684
Locations
πŸ‡ΊπŸ‡Έ

Scottsdale Medical Imaging, Ltd., Scottsdale, Arizona, United States

πŸ‡ΊπŸ‡Έ

Premiere Oncology of Arizona, Scottsdale, Arizona, United States

πŸ‡ΊπŸ‡Έ

Premiere Oncology, A Medical Corporation, Santa Monica,, California, United States

and more 1 locations

Toviaz Post Marketing Surveillance Study

Completed
Conditions
Overactive Bladder
Interventions
First Posted Date
2009-04-10
Last Posted Date
2015-10-21
Lead Sponsor
Pfizer
Target Recruit Count
3000
Registration Number
NCT00879398
Locations
πŸ‡°πŸ‡·

Hankook General Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

πŸ‡°πŸ‡·

Shin Urology Clinic, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

πŸ‡°πŸ‡·

Lee Urology Clinic, Namyangju-si, Gyeonggi-do, Korea, Republic of

and more 72 locations

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Neoplasms
Carcinoma
Cancer
Malignancy
Interventions
Biological: CVX-045
First Posted Date
2009-04-10
Last Posted Date
2010-12-13
Lead Sponsor
Pfizer
Target Recruit Count
40
Registration Number
NCT00879554
Locations
πŸ‡ΊπŸ‡Έ

Pfizer Investigational Site, Philadelphia, Pennsylvania, United States

A Trial In Patients With Advanced Cancer And Leukemia

Phase 1
Completed
Conditions
Neoplasms by Histologic Type
Interventions
First Posted Date
2009-04-08
Last Posted Date
2019-11-12
Lead Sponsor
Pfizer
Target Recruit Count
72
Registration Number
NCT00878189
Locations
πŸ‡ΊπŸ‡Έ

Anschutz Cancer Pavilion, Aurora, Colorado, United States

πŸ‡ΊπŸ‡Έ

University of Colorado Denver CTRC, Aurora, Colorado, United States

πŸ‡ΊπŸ‡Έ

University of Colorado Hospital, Aurora, Colorado, United States

and more 7 locations

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

Phase 1
Completed
Conditions
Age-Related Maculopathy
Eye Diseases
Age-Related Maculopathies
Retinal Degeneration
Macular Degeneration
Interventions
Biological: RN6G
Biological: Placebo
First Posted Date
2009-04-07
Last Posted Date
2015-03-31
Lead Sponsor
Pfizer
Target Recruit Count
57
Registration Number
NCT00877032
Locations
πŸ‡ΊπŸ‡Έ

Dedicated Phase 1, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Retinal Consultants of AZ, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Insight Diagnostic Imaging Center, Phoenix, Arizona, United States

and more 16 locations
Β© Copyright 2025. All Rights Reserved by MedPath